Biocure Technology Inc.
Biocure Technology Inc.
Biocure Technology Inc. is a biopharmaceutical company, specializing in the development and commercialization of major biosimilar products. Biocure is currently conducting pre-clinical trials of its biosimilar candidates of Interferon Beta 1b, PEG-Filgrastim and Ranibizumab as well as CAR-T Cell Therapy.
Biocure Technology Inc. (CURE)
SEDAR Information
Company Info
Capitalization
News Releases
Bulletins
2023-0927 - Halted for Fundamental Change - Biocure Technology Inc. (CURE)
le 18 septembre/September 2023
Trading in the shares of Biocure Technology Inc. will remain halted pending receipt and review of acceptable documentation regarding the Fundamental Acquisition pursuant to CSE Policy 8. This regulatory halt is imposed by Investment Industry Regulatory Organization of Canada, the Market Regulator of the Exchange, pursuant to the provisions of Section 10.9(1) of the Universal Market Integrity Rules.
Advertisement
Publicité